Katherine High joined AskBio in January 2021 as President, Therapeutics, and member of the AskBio Board of Directors. Dr. High is responsible for driving the strategic direction and execution of the company’s preclinical and clinical programs. Most recently, she was a Visiting Professor at Rockefeller University. Previously, she served as President, Head of Research and Development, and a member of the Board of Directors at Spark Therapeutics, where she directed the development and regulatory approval of Luxturna^®, the first gene therapy for genetic disease to obtain regulatory approval in both the United States and Europe. She was a longtime member of the faculty at the University of Pennsylvania and medical staff at The Children’s Hospital of Philadelphia, where she was also an Investigator with the Howard Hughes Medical Institute. She served a five-year term on the U.S. Food and Drug Administration Advisory Committee on Cell, Tissue and Gene Therapies and is a past president of the American Society of Gene & Cell Therapy.

Dr. High received her bachelor’s degree in chemistry from Harvard University, an MD from the University of North Carolina School of Medicine, a business certification from the University of North Carolina Business School’s Management Institute for Hospital Administrators and a master’s degree from the University of Pennsylvania. She is an elected member of the National Academy of Medicine, the American Academy of Arts and Sciences, and the faculty of Pharmaceutical Medicine of the Royal College of Physicians (London).